The Rare Earth Fingerprint Tech – SMX

Unsubscribe

A message from SmallCaps Daily

SMX Emerges as a Critical Shield for U.S. National Security as Iran Conflict Threatens Rare Earth Flows

The strategic importance of rare earth minerals has skyrocketed amid the rising confrontation between the United States and Iran, as these materials underpin the technology, defense, and energy sectors that power national security.

Australia, a leading producer of rare earths, faces pressure to provide secure, verifiable, and compliant supply chains to meet U.S. demands. SMX (Security Matters) Public Limited (NASDAQ: SMX) offers a transformative solution: a molecular identity platform that embeds an indelible, verifiable signature into each mineral, enabling precise origin tracking from mine to market.

By converting supply chains into intelligent, self-verifying networks, SMXaddresses vulnerabilities that can otherwise be exploited during geopolitical instability, including counterfeiting, tampering, and unauthorized diversion of critical resources.

Operating from Singapore and leveraging Southeast Asia’s stable environment, SMX delivers a globally neutral, resilient, and scalable platform for supply-chain security.

Its technology not only verifies materials but strengthens regulatory compliance, industrial accountability, and defense readiness.

In times of conflict, such as the current Iran-U.S. tensions, this capability becomes indispensable: it ensures that essential rare earths are authenticated, traceable, and shielded from interference.

For governments, multinational enterprises, and defense partners, SMXrepresents more than innovation—it is a safeguard against uncertainty, a reinforcement of national security, and a commitment to transparency in a world where trust is fragile.

Discover why SMX is leading the charge in securing the world’s critical minerals

Further Reading from MarketBeat Media

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Submitted by Nathan Reiff. Publication Date: 3/12/2026. 

Microscopic view of cancer cells on a pathology slide, representing oncology research and cancer drug development in biotech.

Key Points

  • Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
  • Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
  • Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
  • Special Report: You’ve Got to See This Pattern Before 2025 Picks Up… (From Stock Wire News)

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with tailored mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales.

Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond therapeutic promise, these drugs could help the firms move toward greater stability and, potentially, long-term profitability. That said, both remain high-risk investments: each faces clinical, regulatory, or commercial hurdles that could limit upside even as the rewards for success are substantial.

Iovance’s Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle

Stopping the Deadliest Animal on Earth (Ad)

Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.

Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.

With $6.4M in sales in just four years, they’re getting ready for the next step.Become a Med-X Shareholder Before Their Nasdaq Plans Unfold

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, jumping nearly 37% in a week when the S&P 500 slipped about 1%. That rally added to IOVA’s strong year-to-date performance, with shares more than doubling so far. Still, with a consensus price target of $8.88, Wall Street sees further upside—implying roughly 71% more gains from current levels.

The main catalyst behind Iovance’s move is its lead therapy, Amtagvi, a T‑cell immunotherapy for certain types of melanoma.

Amtagvi has been approved in the United States since 2024 and is building commercial momentum, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company’s IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak annual U.S. sales.

Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track designation for non‑small cell lung cancer and is being evaluated for other tumor types.

Some of Iovance’s outperformance this year also reflects its Q4 2025 earnings report, issued in late February, in which the company posted narrower‑than‑expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year.

Iovance is still considered a small (about $2 billion) biotech, and despite the rally, analysts remain cautious—about half of its roughly dozen ratings are Hold or Sell. Risks are significant: in addition to typical small‑biotech concerns, Amtagvi is a personalized therapy that is costly and complex to manufacture. That manufacturing profile could constrain margins and profitability even as demand increases.

Massive Sales Growth for ImmunityBio’s Bladder Cancer Drug

Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year‑to‑date performance far outpaces Iovance’s. IBRX shares are up nearly 300% in 2026, and analysts remain optimistic: the consensus price target is $13.60, roughly 70% above the stock’s current level.

ImmunityBio’s primary growth driver is Anktiva, a treatment for certain forms of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—one of several recent approvals globally.

Anktiva is already material to the company’s top line: the drug generated $113 million in sales last year, a roughly 700% year‑over‑year increase.

Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional regulatory designations.

Despite the strong recent performance, IBRX remains speculative and risky.

The company reported a full‑year net loss of $351 million for 2025 as R&D and other expenses remain elevated. Analysts, however, are relatively bullish on ImmunityBio compared with Iovance: six out of seven covering the stock rate it a Buy or equivalent.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AMnewsletter that covers stories that will impact the stock market each day.

This email communication is a sponsored message provided by SmallCaps Daily, a third-party advertiser of The Early Bird and MarketBeat. 


This message is a paid advertisement for SMX (NASDAQ: SMX) from SmallCaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either SmallCaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding SMX (NASDAQ: SMX) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and SMX (NASDAQ: SMX).


If you need help with your subscription, feel free to contact our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States..

Check This Out: [VIDEO] OpenAI IPO filing leaked – ticker revealed (delete after reading) (From The Oxford Club)

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment